Cargando…

M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer

Background: Lung cancer is the leading cause of cancer-related death worldwide. Although the macrophages can affect the development of tumor, the contribution of macrophages to the prognosis of non-small-cell lung cancer (NSCLC) is still controversial. Moreover, anti-PD-1 therapy can redirect macrop...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Lili, Che, Xiaofang, Qiu, Xueshan, Li, Zhi, Yang, Bowen, Wang, Shuo, Hou, Kezuo, Fan, Yibo, Qu, Xiujuan, Liu, Yunpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613613/
https://www.ncbi.nlm.nih.gov/pubmed/31308749
http://dx.doi.org/10.2147/CMAR.S199832
_version_ 1783433064733474816
author Cao, Lili
Che, Xiaofang
Qiu, Xueshan
Li, Zhi
Yang, Bowen
Wang, Shuo
Hou, Kezuo
Fan, Yibo
Qu, Xiujuan
Liu, Yunpeng
author_facet Cao, Lili
Che, Xiaofang
Qiu, Xueshan
Li, Zhi
Yang, Bowen
Wang, Shuo
Hou, Kezuo
Fan, Yibo
Qu, Xiujuan
Liu, Yunpeng
author_sort Cao, Lili
collection PubMed
description Background: Lung cancer is the leading cause of cancer-related death worldwide. Although the macrophages can affect the development of tumor, the contribution of macrophages to the prognosis of non-small-cell lung cancer (NSCLC) is still controversial. Moreover, anti-PD-1 therapy can redirect macrophages from an M2 to an M1 phenotype, suggesting that tumor PD-L1 may affect the prognostic role of macrophages. Therefore, in this study, we aimed to display a macrophage landscape to clarify the function of macrophages, considering the localization and polarization of the macrophages, and evaluate the effect of M2 macrophages and tumor PD-L1 in combination on the prognosis of NSCLC. Methods: We performed multiplex quantitative immunofluorescence staining of pan-cytokeratin (CK), CD68, CD163, PD-L1, and DAPI on one tissue specimen simultaneously from 137 NSCLC patients. Results: M2 macrophages, involved marginM2 (M2 macrophages in tumor stroma), and centralM2 (M2 macrophages infiltrating into tumor islets) increased as the tumor stage increased. More macrophages were found in lung squamous cell carcinoma (LUSC) patients, patients with wild-type EGFR, and smokers than in patients with lung adenocarcinoma (LUAD), patients with EGFR mutations, and non-smokers. Infiltration of centralM2 was an independent prognostic factor of poor overall survival (OS) and disease-free survival (DFS) for NSCLC patients (P<0.05), which was superior to total macrophages and total M2 macrophages. Moreover, patients with centralM2(less)PD-L1(−) tumors showed the best OS and DFS, while the patients with centralM2(more)PD-L1(+) tumors showed the worst OS and DFS, and the two groups with centralM2(less)PD-L1(+) and centralM2(more)PD-L1(−) were in the middle (P=0.002, 0.034, respectively). Conclusion: Tumor islet-infiltrating M2 macrophages influence the prognosis of NSCLC patients. The analysis of M2 macrophages and tumor PD-L1 in combination may enhance the accuracy of prognostic prediction. This study provides a new understanding of macrophages in the development of NSCLC through the analysis of macrophage landscape.
format Online
Article
Text
id pubmed-6613613
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66136132019-07-15 M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer Cao, Lili Che, Xiaofang Qiu, Xueshan Li, Zhi Yang, Bowen Wang, Shuo Hou, Kezuo Fan, Yibo Qu, Xiujuan Liu, Yunpeng Cancer Manag Res Original Research Background: Lung cancer is the leading cause of cancer-related death worldwide. Although the macrophages can affect the development of tumor, the contribution of macrophages to the prognosis of non-small-cell lung cancer (NSCLC) is still controversial. Moreover, anti-PD-1 therapy can redirect macrophages from an M2 to an M1 phenotype, suggesting that tumor PD-L1 may affect the prognostic role of macrophages. Therefore, in this study, we aimed to display a macrophage landscape to clarify the function of macrophages, considering the localization and polarization of the macrophages, and evaluate the effect of M2 macrophages and tumor PD-L1 in combination on the prognosis of NSCLC. Methods: We performed multiplex quantitative immunofluorescence staining of pan-cytokeratin (CK), CD68, CD163, PD-L1, and DAPI on one tissue specimen simultaneously from 137 NSCLC patients. Results: M2 macrophages, involved marginM2 (M2 macrophages in tumor stroma), and centralM2 (M2 macrophages infiltrating into tumor islets) increased as the tumor stage increased. More macrophages were found in lung squamous cell carcinoma (LUSC) patients, patients with wild-type EGFR, and smokers than in patients with lung adenocarcinoma (LUAD), patients with EGFR mutations, and non-smokers. Infiltration of centralM2 was an independent prognostic factor of poor overall survival (OS) and disease-free survival (DFS) for NSCLC patients (P<0.05), which was superior to total macrophages and total M2 macrophages. Moreover, patients with centralM2(less)PD-L1(−) tumors showed the best OS and DFS, while the patients with centralM2(more)PD-L1(+) tumors showed the worst OS and DFS, and the two groups with centralM2(less)PD-L1(+) and centralM2(more)PD-L1(−) were in the middle (P=0.002, 0.034, respectively). Conclusion: Tumor islet-infiltrating M2 macrophages influence the prognosis of NSCLC patients. The analysis of M2 macrophages and tumor PD-L1 in combination may enhance the accuracy of prognostic prediction. This study provides a new understanding of macrophages in the development of NSCLC through the analysis of macrophage landscape. Dove 2019-07-04 /pmc/articles/PMC6613613/ /pubmed/31308749 http://dx.doi.org/10.2147/CMAR.S199832 Text en © 2019 Cao et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Cao, Lili
Che, Xiaofang
Qiu, Xueshan
Li, Zhi
Yang, Bowen
Wang, Shuo
Hou, Kezuo
Fan, Yibo
Qu, Xiujuan
Liu, Yunpeng
M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer
title M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer
title_full M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer
title_fullStr M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer
title_full_unstemmed M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer
title_short M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer
title_sort m2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613613/
https://www.ncbi.nlm.nih.gov/pubmed/31308749
http://dx.doi.org/10.2147/CMAR.S199832
work_keys_str_mv AT caolili m2macrophageinfiltrationintotumorisletsleadstopoorprognosisinnonsmallcelllungcancer
AT chexiaofang m2macrophageinfiltrationintotumorisletsleadstopoorprognosisinnonsmallcelllungcancer
AT qiuxueshan m2macrophageinfiltrationintotumorisletsleadstopoorprognosisinnonsmallcelllungcancer
AT lizhi m2macrophageinfiltrationintotumorisletsleadstopoorprognosisinnonsmallcelllungcancer
AT yangbowen m2macrophageinfiltrationintotumorisletsleadstopoorprognosisinnonsmallcelllungcancer
AT wangshuo m2macrophageinfiltrationintotumorisletsleadstopoorprognosisinnonsmallcelllungcancer
AT houkezuo m2macrophageinfiltrationintotumorisletsleadstopoorprognosisinnonsmallcelllungcancer
AT fanyibo m2macrophageinfiltrationintotumorisletsleadstopoorprognosisinnonsmallcelllungcancer
AT quxiujuan m2macrophageinfiltrationintotumorisletsleadstopoorprognosisinnonsmallcelllungcancer
AT liuyunpeng m2macrophageinfiltrationintotumorisletsleadstopoorprognosisinnonsmallcelllungcancer